Enjoy complimentary customisation on priority with our Enterprise License!
The thrombosis drugs market share is expected to increase by USD 16.24 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 9.67%.
This thrombosis drugs market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers thrombosis drugs market segmentation by indication (pulmonary embolism and DVT) and geography (North America, Europe, Asia, and Rest of World (ROW)). The thrombosis drugs market report also offers information on several market vendors, including Aspen Pharmacare Holdings Ltd., AuroMedics Pharma LLC, Baxter International Inc., Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., F. Hoffmann La Roche Ltd., GoodRx Holdings Inc., Grifols SA, GlaxoSmithKline Plc, Inari Medical Inc., Italfarmaco Spa, Johnson and Johnson, Pfizer Inc., Sanofi SA, Vasudha Pharma Chem Ltd., and Viatris Inc. among others.
Download the Free Report Sample to Unlock the Thrombosis Drugs Market Size for the Forecast Period and Other Important Statistics
The introduction of novel oral anticoagulants is notably driving the thrombosis drugs market growth, although factors such as strong side-effects of anticoagulants may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the thrombosis drugs industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Thrombosis Drugs Market Driver
One of the key factors driving the global thrombosis drugs industry growth is the introduction of novel oral anticoagulants. The market has witnessed the launch of a direct thrombin inhibitor called dabigatran and anti-Xa agents, including ELIQUIS (apixaban), SAVAYSA and LIXIANA (edoxaban), and XARELTO (rivaroxaban), that are classified as new-age oral anticoagulants. These novel oral anticoagulants have shown high efficacy and a higher safety profile for the treatment of thrombosis. They have higher efficacy compared with vitamin K antagonists as the dose does not need to be adjusted, and patients do not need to be monitored. Oral anticoagulants significantly reduce the risk of major bleeding. They have also been highly effective in the treatment of acute thrombosis. The development and launch of such drugs are expected to result in significant growth of the market during the forecast period.
Key Thrombosis Drugs Market Trend
Sedentary lifestyle is one of the key thrombosis drugs market trends that is expected to impact the industry positively in the forecast period. Old age and obesity are two of the most common causes of thrombosis. Globally, a sedentary lifestyle is resulting in an increase in the number of thrombosis cases. As per a study conducted by the Department of Biological Sciences, Dublin Institute of Technology, the average food consumption at a global level increased from 2,411 kcal per day in 1969 to 2,950 Kcal per day in 2015 and is expected to reach 3,040 kcal by 2030. The average food consumption in the US is significantly higher than the global rate and is about 3,750 kcal per day. The increase in sedentary behavior is leading to the rise in the prevalence of obesity across the world, thus increasing the risk of thrombosis. The increasing number of cases of thrombosis caused by these factors is expected to contribute to the growth of the market during the forecast years.
Key Thrombosis Drugs Market Challenge
One of the key challenges to the global thrombosis drugs industry growth is the strong side effects of anticoagulants. Anticoagulants decrease the ability of blood to clot, and they slow down the blood clotting process. As a result, the flow of blood becomes uncontrollable, even in cases of small cuts. The long-term use of anticoagulants is associated with increased cardiovascular risks, such as strokes and heart attacks. Some of the other side effects associated with the use of anticoagulants include severe bruising, prolonged nosebleeds, and vomiting blood. The use of anticoagulants is also associated with severe back pain, chest pain, dizziness, headaches, and jaundice. The increasing awareness of the side effects of anticoagulants is expected to hinder the growth of the global thrombosis drugs market during the forecast period.
This thrombosis drugs market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
Technavio categorizes the global thrombosis drugs market as a part of the pharmaceutical market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the thrombosis drugs market during the forecast period.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the thrombosis drugs market encompasses successful business strategies deployed by the key vendors. The thrombosis drugs market is fragmented and the vendors are deploying growth strategies such as investment in R and D to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The thrombosis drugs market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Our report provides extensive information on the value chain analysis for the thrombosis drugs market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
For more insights on the market share of various regions Request for a FREE sample now!
44% of the market's growth will originate from North America during the forecast period. The US is the key market for thrombosis drugs in North America. Market growth in this region will be faster than the growth of the market in Rest of World (ROW).
The increasing prevalence of DVT and pulmonary embolism, the increasing awareness of the severity of the disease, and the advanced healthcare system will facilitate the thrombosis drugs market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
The ongoing COVID-19 outbreak positively impacted the growth of the regional thrombosis drugs market in 2020-2021, owing to the increasing need for anticoagulant treatment for patients with COVID-19-induced thrombosis indications. This has prompted vendors to increase production to meet the growing demand. Thus, the regional market in focus will register growth during the forecast period.
To gain further insights on the market contribution of various segments Request for a FREE sample
The thrombosis drugs market share growth by the pulmonary embolism segment will be significant during the forecast period. Advances in the pipeline of novel molecules and the approval of antidotes for oral anticoagulants are expected to significantly drive the growth of the segment during the forecast years.
This report provides an accurate prediction of the contribution of all the segments to the growth of the thrombosis drugs market size and actionable market insights on post COVID-19 impact on each segment.
Thrombosis Drugs Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 9.67% |
Market growth 2022-2026 |
$ 16.24 billion |
Market structure |
Fragmented |
YoY growth (%) |
9.13 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 44% |
Key consumer countries |
US, France, Norway, UK, and Japan |
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
Key companies profiled |
Aspen Pharmacare Holdings Ltd., AuroMedics Pharma LLC, Baxter International Inc., Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., F. Hoffmann La Roche Ltd., GoodRx Holdings Inc., Grifols SA, GlaxoSmithKline Plc, Inari Medical Inc., Italfarmaco Spa, Johnson and Johnson, Pfizer Inc., Sanofi SA, Vasudha Pharma Chem Ltd., and Viatris Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.